Focused On-demand Library for Type-2 angiotensin II receptor

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P50052

UPID:

AGTR2_HUMAN

Alternative names:

Angiotensin II type-2 receptor

Alternative UPACC:

P50052; B2R9V1; Q13016; Q6FGY7

Background:

The Type-2 angiotensin II receptor, also known as the Angiotensin II type-2 receptor, plays a crucial role in vascular physiology. It acts as a receptor for angiotensin II, a peptide that induces vasoconstriction, signaling primarily through non-canonical pathways independent of G-protein and beta-arrestin. This receptor also collaborates with MTUS1 to inhibit ERK2 activation and cell proliferation, highlighting its regulatory function in cell growth.

Therapeutic significance:

Understanding the role of the Type-2 angiotensin II receptor could open doors to potential therapeutic strategies. Its involvement in non-canonical signaling pathways and cell proliferation regulation presents a unique opportunity for targeted drug development, offering new avenues for treating conditions related to vascular dysfunction and abnormal cell growth.